Brief: Novocure Provides FDA Update on Optune Mya Approval Application for Lung Cancer Brain Metastases
BRIEF-Novocure Provides FDA Update on Optune Mya Approval Application for Lung Cancer Brain Metastases Nov 9 (Reuters) - NovoCure Limited NVCR.O:
NOVOCURE PROVIDES REGULATORY UPDATE ON U.S. FDA PREMARKET APPROVAL APPLICATION FOR OPTUNE MYA® FOR BRAIN METASTASES FROM NON-SMALL CELL LUNG CANCER
NOVOCURE - FDA CITES UNCERTAINTY IN CLINICAL BENEFIT FOR OPTUNE MYA PMA NON-APPROVAL
NOVOCURE - FDA DOES NOT RAISE SAFETY CONCERNS FOR OPTUNE MYA
NOVOCURE - TO MEET FDA TO EXPLORE PMA APPROVAL OPTIONS WITHOUT ADDITIONAL STUDIES
NOVOCURE - RECEIVES FDA NOT APPROVABLE LETTER FOR OPTUNE MYA PMA APPLICATION
Source text: ID:nBw8GL7t8a
Further company coverage: NVCR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NovoCure
See all newsBrief: Novocure’s PANOVA-3 Quality of Life, Pain Data Published in JAMA Network Open
US FDA declines to approve Novocure's lung cancer device
Brief: Novocure Provides FDA Update on Optune Mya Approval Application for Lung Cancer Brain Metastases
NovoCure Limited reports results for the quarter ended September 30 - Earnings Summary
Switzerland's Novocure Q3 revenue rises 16%, beats estimates